Comparative Efficacy and Tolerability of Drug Treatments for Bipolar Disorder

CNS Drugs

Volumn 15, Issue 9, 2001, Pages 701-718

  Strakowski, Stephen M ^a   DelBello, Melissa P ^a   Adler, Caleb M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM CHLORIDE; NEUROLEPTIC AGENT; TRANQUILIZER;

ANIMAL; BIPOLAR DISORDER; COMPARATIVE STUDY; DRUG INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG INTERACTIONS; HUMANS; LITHIUM CHLORIDE;

EID: 0035232859     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115090-00004     Document Type: Article

References (128)

1. Janicak PG, Bresnahan DB, Sharma R, et al. A comparison of thiothixene with chlorpromazine in the treatment of mania. J Clin Psychopharmacol 1988; 8: 33-7
2. Poolsup N, Po ALW, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000; 25 (2): 139-56
3. Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999 Aug; 156(8): 1264-6
4. Goodwin FK, Jamison KR. Manic-depressive illness. Nev. York. Oxford University Press, 1990
5. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997 Jan; 54 (1): 37-42
6. Strakowski S, McElroy S, Keck P. Clinical efficacy of valproate in bipolar illness' comparisons and contrasts with lithium In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 143-57
7. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial, Int Clin Psychopharmacol 1999; 14 (6): 339-43
8. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May-Jun: 21 (3): 176-80
9. Zornberg GL, Pope Jr HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993 Dec; 13 (6): 397-408
10. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100: 406-17
11. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 77-84
12. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987 Mar; 48 (3): 89-93
13. Small J, Klapper M, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991 Oct; 48 (10): 915-21
14. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204
15. Greil W, Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders -a randomised study. J Affect Disord 1997; 43 (2): 151-61
16. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar disorder. Acta Psychiatr Scand 1992; 85: 114-8
17. Derucoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium. Carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-8
18. Freeman T, Clothier J, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992 Jan; 149 (1): 108-11
19. Bowden C, Brugger A, Swann A. et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994 Mar 23-30; 271 (12): 918-24
20. Bowden C, Calabrese JR, McElroy S, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry May 2000; 57: 481-9
21. Prien R, Point P, Caffey E, et al. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972 Feb: 26: 146-53
22. Takahashi R, Sakuma A, Itoh K, et al. Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Arch Gen Psychiatry 1975 Oct; 32: 1310-8
23. Shopsin B, Gershon S, Thompson H. et al. Psychoactive drugs in mania. Arch Gen Psychiatry 1975 Jan: 32: 34-42
24. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000 Mar: 12 (1): 5-10
25. Post RM, Pazzaglia PJ, Ketter TA, et al. Carbamazepine and nimodipine in refractory bipolar illness: efficacy and mechanisms. In: Halbreich U, Montgomery S, editors. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press Inc., 2000: 77-110
26. Keck Jr PE, McEIroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 Suppl, 6. 74-81
27. McElroy SL, Keck Jr PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48: 539-57
28. Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. In: Emrich H, Schiwy W, Silverstone T, editors, Carbamazepine and oxcarbazepine in psychiatry. London: CNS Publishers, 1990: 83-8
29. Müller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 134-47
30. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50
31. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Press Inc., 1997
32. Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996; 71: 778-6
33. Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994 Mar; 8 (2): 211-33
34. Albani F, Riva R, Baruzzi A. Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 1995; 28: 235-44
35. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990 Dec; 24 (12): 1214-9
36. Van Amelsvoort T, Bakshi T, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994 Jan-Feb; 35 (1): 181-8
37. Shorvon S. Oxcarbazepine; a review. Seizure 2000 Mar; 9 (2): 75-9
38. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979; 66 (3): 211-7
39. Grossi E, Sacchetti E, Vita A, et al Carbamazepine versus chlorpromazine in mama: a double blind trial. In: Emrich HM, Okuma T, Muller AA, editors. Anuconvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 177-87
40. Pope Jr HG, McEIroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62-8
41. Keck Jr PE, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993 Aug. 54 (8): 305-8
42. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993 Nov 4; 329 (19): 1383-8
43. Bauer J, Jarre A, Klingmuller D. et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000 Sep; 41 (2): 163-7
44. Rasgon N, Altshuler L. Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder a preliminary report. J Clin Psychiatry 2000 Mar; 61 (3): 173-8
45. Jennings H, Romanelli F. The use of vaiproic acid in HIV-positive patients. Ann Pharmacother 1999 Oct; 33: 1113-6
46. McElroy SL, Keck P, Stanton S, et al, A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996 Apr; 57 (4): 142-6
47. Tohen M, Baker RW, Altshuler L, et al. Olanzapine versus divalproex for the treatment of acute mania [abstract]. European College of Neuropsychopharmacology Annual Meeting; 2000 Sep 9-13: Munich
48. Labbate L, Rubey R. Lamotrigine for treatment-refractory bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1317
49. Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997 Dec; 58 (12): 522-7
50. Calabrese J, Fatemi S, Woyshville M. Antidepressant effects, of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996; 153: 1236
51. Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 1998 Oct; 38 (3): 185-91
52. Kusumakar V, Yatham L. Lamotrigine treatment of rapid cycling bipolar disorder [letter]. Am J Psychiatry 1997; 154: 1171-2
53. Walden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996 Sep: 29 (5): 193-5
54. Fogelson D, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997; 58: 271-3
55. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185-9
56. Kotler M, Matar M. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21: 65-7
57. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999 Jul: 156: 1019-23
58. Weisler R, Risner ME, Ascher J, et al. Use of lamotrigine in the treatment of bipolar disorder [abstract]. In: The American Psychiatric Association Annual Meeting New Research Program and Abstracts. Washington, DC. American Psychiatric Association, 1994 May: 216
59. Suppes T, Brown E, McElroy S, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95-8
60. Bowden CL, Calabrese JR, McElroy SL, et al The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953-8
61. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-14
62. Anand A, Oren DA, Berman RM, et al. Lamotrigine treatment of lithium failure in outpatient mania - a double-blind, placebo-controlled trial [abstract]. In: Scares JC, Gershon S, editors. Bipolar disorders abstract book. Third International Conference on Bipolar Disorder; 1999 Jun 17-19: Pittsburgh (PA) Copenhagen: Munksgaard, 1999: 23
63. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Am J Psychiatry 1999 Feb; 60: 79-88
64. Sabers A, Gram L. Newer anticonvulsants' comparative review of drug interactions and adverse effects. Drugs 2000 Jul; 60 (1): 23-33
65. Messenheimer J A. Rash in adult and pediatric patients treated with larnotrigine. Can J Neurol Sci 1998 Nov; 25 (4): S14-8
66. Gilman JT. Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995 Feb; 29 (2): 144-51
67. Bozikas V, Vartzopoulos D, Phocas C, et al. Lamotrigine-induced rash after sun exposure [letter]. Am J Psychiatry 1999; 156: 2015-6
68. Isojärvi JT, Tapanainen JS. Valproate, hyperandrogenism. and polycystic ovaries: a report of 3 cases. Arch Neurol 2000 Jul; 57 (7): 1064-8
69. Husain AM, Carwile ST, Miller PP, et al. Improved sexual function in three men taking lamotrigine for epilepsy. South Med J 2000 Mar; 93 (3): 335-6
70. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245-51
71. Chengappa KNR, Rathore D, Levine J. et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53
72. Gordon A, Price L. Mood stabilization and weight loss with topiramate [letter]. Am J Psychiatry 1999; 156: 968-9
73. Calabrese JR, Keck Jr PE, McElroy SL, et al. Topiramate in severe treatment-refractory mania [abstract]. In: The American Psychiatric Association Annual Meeting; 1998 May 30-Jun 4; Toronto, Canada. Washington, DC: American Psychiatric Association, 1998: 121-2
74. Normann C, Langosch J, Schaerer L, et al. Treatment of acute mania with topiramate [letter]. Am J Psychiatry 1999; 156: 2014
75. Kusumakar V, Kakshmi N, Yatham MB, et al. Topiramate in rapid cycling bipolar women [abstract]. In: The American Psychiatric Association Annual Meeting; 1999 May 15-20; Washington. DC. Washington, DC: American Psychiatric Association, 1999: 200
76. McElroy S, Suppes T, Keck P. et al Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-33
77. Hussain M. Treatment of bipolar depression with topiramate [abstract]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco
78. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996: 37 Suppl. 2: S18-22
79. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000 May; 61 (5): 368-72
80. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999: 53 (5 Suppl. 2): S53-67
81. Rosenfeld WE. Topiramate: a review of preclinical, pharmaco-kinetic, and clinical data. Clin Ther 1997 Nov-Dec: 19 (6): 1294-308
82. Craw ford P. An audit of topiramate use in a general neurology clinic Seizure 1998 Jun: 7 (3): 207-11
83. Hamer HM, Knake S, Schomburg U, et al. Vaiproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Jan 11 ; 54 (1): 230-2
84. Solomon GE. Vaiproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000 Aug 22: 55 (4): 606
85. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder' a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000: 2 (3 Pt 2): 249-55
86. Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am J Psychiatry 1999 Dec; 156 (12): 2014-5
87. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60: 759-62
88. Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 707-15
89. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000 Jan: 9 (1): 65-70
90. Charles CL, Stoesz L, Tbllefson G. Zonisamide-induced mania. Psychosomatics 1990; 31 (2): 214-7
91. Keck Jr PE, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000: 61 Suppl. 4: 33-8
92. McElroy SL, Keck Jr PE, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 3: 14-26
93. Muller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled multicenter study. J Clin Psychopharmacol 2000; 20: 195-203
94. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226-37
95. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis Psychosomatics 1984; 25: 135-8
96. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999 May: 156 (5): 702-9
97. Tohen M, Jacobs, TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841-9
98. Tohen M, Chengappa KNR, Suppes TR, et al. Efficacy of olanzapine added to valproate or lithium in the treatment of bipolar 1 disorder [abstract]. American Psychiatric Association Annual Meeting; 2000 May 13-18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000
99. Tohen MF, Jacobs TG, Gannon KS, et al Olanzapine: acute and long-term efficacy in bipolar I patients Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S247
100. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998 Oct 15; 44 (8): 778-83
101. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999 Jan; 174: 23-30
102. Sachs GS. Safety and efficacy of risperidone vs. placebo vs. haloperidol as add-on therapy to mood stabilizers in treatment of the manic phase of bipolar disorder [abstract; board 35]. 38th Annual Meeting of American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco
103. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-28
104. Davis JM, Janicak PG. Risperidone: a new. novel (and better?) antipsychotic. Psychiatric Ann 1996 Feb; 26 (2) 1-10
105. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
106. Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-110
107. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999 Aug: 156 (8): 1164-9
108. Zarate Jr CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-7
109. Barbini B, Scherillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997; 12: 109-12
110. Calabrese JR, Kimmel SA, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-64
111. Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000 Jun; 157 (6): 982-6
112. Lieberman J, Safferman A. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Lapierre Y, Jones B, editors. Clozapine in treatment-resistant schizophrenia. Royal Society of Medicine Services International Congress and Symposium Series. No. 185. London: Royal Society of Medicine Services Ltd., 1992 Jun
113. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance Br J Psychiatry 1999 Dec; 175: 576-80
114. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157 (6): 975-81
115. Ghaemi SN, Katzow JJ The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999; 11: 137-40
116. Dunayevich E, Strakowski SM. Seroquel in treatment-resistant mania. Am J Psychiatry 2000; 157: 1341
117. Zarate Jr CA, Rothschild A, Fletcher KE, et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000 Mar; 61 (3): 185-9
118. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156 (11): 1686-96
119. Keck Jr PE, Ice K. A three-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania [abstract]. The American Psychiatric Association Annual Meeting; 2000 May 13-18; Chicago (IL). Washington, DC: American Psychiatric Association, 2000 116-7
120. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy, dilemmas and guidelines. Am J Psychiatry 1996 May; 153 (5): 592-606
121. Ortho-McNeil Pharmaceuticals. Topamax® product insert. Raritan (NJ): Ortho-McNeil Pharmaceuticals, 1999
122. Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000 Jan; 182: 159-63
123. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399-403
124. Trixler M, Tenyi T. Antipsychotic use in pregnancy: what are the best treatment options? Drug Saf 1997 Jun; 16 (6): 403-10
125. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guidelines Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec. No.: 1-104
126. Freeman MP, Stell AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998 Jan; 155 (1): 12-21
127. Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy, Psychopharmacol Bull 1998; 34: 339-46
128. Leibenluft E. Women and bipolar disorder; an update. Bull Menninger Clin 2000; 64: 5-17